InMed Pharmaceuticals Inc. (INM) News
Filter INM News Items
INM News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
INM News Highlights
- For INM, its 30 day story count is now at 6.
- Over the past 6 days, the trend for INM's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- The most mentioned tickers in articles about INM are RARE, CBT and DRUG.
Latest INM News From Around the Web
Below are the latest news stories about InMed Pharmaceuticals Inc that investors may wish to consider to help them evaluate INM as an investment opportunity.
InMed Pharmaceuticals Inc. (INM) CEO Eric Adams on Q2 2022 Results - Earnings Call TranscriptInMed Pharmaceuticals Inc. (INM) Q2 2022 Earnings Conference Call February 15, 2022 14:00 ET Corporate Participants Colin Clancy - Senior Director of Investor Relations Eric Adams - President and Chief Executive Officer Bruce Colwill - Chief Financial Officer Eric Hsu - Senior Vice President, Preclinical Research and Development Alexandra Mancini... |
InMed Pharmaceuticals (INM): Generating Commercial Sales of CBC and CBTLONDON, UK / ACCESSWIRE / February 16, 2022 / InMed Pharmaceuticals' (INM's) Q222 financial results reflect its evolution from a pure-play biotech firm to one with commercial sales to the health and wellness market, with revenues of $0. As of January, it also began selling cannabicitran (CBT) to the health and wellness market. |
InMed Pharmaceuticals Strengthens its Commercial Leadership Team with the Appointment of Vice President of Sales and Marketing for BayMedicaVANCOUVER, British Columbia, Feb. 15, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, is pleased to announce the appointment of Gerard (Jerry) P. Griffin III as Vice President of Sales and Marketing at BayMedica, a wholly owned subsidiary of InMed. Mr. Griffin will oversee the commercialization of BayMedica’s health and wellness business including the exi |
InMed Pharmaceuticals Inc. (INM) Reports Q2 Loss, Tops Revenue EstimatesInMed Pharmaceuticals Inc. (INM) delivered earnings and revenue surprises of -29.17% and 6%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock? |
InMed Pharmaceuticals Reports Second Quarter Fiscal 2022 Financial Results and Provides Business UpdateCompleted acquisition of BayMedica, a rare cannabinoid manufacturing and commercialization company in the health and wellness sectorStrengthened IP with patent filing for use of rare cannabinoids for the treatment of neurodegenerative diseasesCommercial rollout of an additional rare cannabinoid, CBT- first of several rare cannabinoid launches planned for the first half of 2022Advanced the pharmaceutical drug development programs in EB, glaucoma and neurodegenerative diseases VANCOUVER, British C |
InMed Pharmaceuticals to Report Second Quarter Fiscal 2022 Financial Results and Business Update on February 15, 2022VANCOUVER, British Columbia, Feb. 10, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, will report financial results on Tuesday, February 15, 2022 for the second quarter of fiscal year 2022, ending December 31, 2021. Conference Call & Webcast*:Tuesday, February 15, 2022, at 11:00 AM Pacific Time, 02:00 PM Eastern TimeUS/CANADA Participant Toll-Free Dial-In |
InMed launches B2B sales of rare cannabinoid cannabicitranInMed Pharmaceuticals < |
InMed Launches Cannabicitran (CBT), Expanding its Rare Cannabinoid Portfolio for the Health and Wellness SectorCBT is the first of several rare cannabinoid launches planned for the first half of 2022; includes CBDV and THCVExpands the Company’s rare cannabinoid product portfolio, which also includes cannabichromene (CBC)Strengthens leadership position in commercial scale production of high demand rare cannabinoids VANCOUVER, British Columbia, Jan. 19, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and comm |
InMed Pharmaceuticals'' Issues Annual Shareholder LetterInMed Pharmaceuticals (NASDAQ: INM ), a leader in the development, manufacturing, and commercialization of rare cannabinoids, has released a shareholder letter. The letter, from president and CEO Eric A. Adams, provided INM shareholders with a company update, including a look at key milestones the company had reached, including the acquisition of BayMedica, which Adams said positioned InMed as a clear leader in rare cannabinoid manufacturing. Adams also noted that the company continued to make significant strides with its proprietary IntegraSyn(TM) program and is advancing its pharmaceutical programs, thanks in large part to the library of novel cannabinoid analogs developed by BayMedica. The company also initiated a phase 2 trial of its INM-755 program for the treatment of epidermolysi... |
InMed Issues Annual Letter to Shareholders Highlighting Key Accomplishments from 2021 and Providing 2022 OutlookVANCOUVER, British Columbia, Jan. 05, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the development, manufacturing and commercialization of rare cannabinoids, today issued the following letter from President and CEO Eric A. Adams. Dear Shareholders, Colleagues, and Business Partners, I’d like to start off by sending you warm wishes for a healthy and prosperous 2022. While another wave of the COVID-19 pandemic continues to bring global u |